Stock IDIA IDORSIA LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Idorsia Ltd

Equities

IDIA

CH0363463438

Market Closed - Swiss Exchange
Other stock markets
 11:30:11 2024-04-19 am EDT 		5-day change 1st Jan Change
1.97 CHF +1.03% Intraday chart for Idorsia Ltd +5.91% -6.81%
Apr. 11 Swiss Market Index Falls as ECB Signals June Rate Cut MT
Apr. 11 Idorsia to Revise July 2024 Convertible Bond Terms, Conditions MT

Summary

  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
IDORSIA LTD Stock Idorsia Ltd
-6.81% 383M
A-
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
B+
ARGENX SE Stock argenx SE
-1.80% 21.66B
B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
B+
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IDIA Stock
  4. Ratings Idorsia Ltd